Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.

The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Sufferers of mild cognitive decline can now turn to Nestlé Health Science's new ketogenic drink BrainXpert Energy Complex. Initially available in the UK as a food for special medical purposes, Nestlé's clinically tested brain health solution will soon be rolled out to 15 countries across the world.